Summary: In a 24-week trial in type 2 diabetes, high-phenolic extra virgin olive oil from Galician olives reduced insulin resistance compared with refined olive oil, but did not change lipids or blood pressure, with glycaemic benefits limited to underpowered obese and insulin-resistant subgroups.
PICO Summary
| Element | Detail |
|---|---|
| Population | 116 adults with type 2 diabetes; 24-week randomised parallel trial, Galicia, Spain. |
| Intervention | 30 mL/day of high-phenolic extra virgin olive oil from native Galician olives. |
| Comparison | Control advised to minimise EVOO, preferring refined olive oil blends. |
| Outcome | The intervention group had a significant reduction in insulin resistance (HOMA-IR). No significant change in lipid profile or blood pressure in either group; both groups had modest weight/BMI reductions. Falls in fasting glucose, average glucose, and HbA1c appeared in obese and insulin-resistant subgroups, but these were underpowered and should be interpreted cautiously. |
Galician high-phenolic olive oil in T2D
RCT · type 2 diabetes · 24 weeks
High-phenolic Galician olive oil significantly reduced insulin resistance (HOMA-IR) versus refined oil over 24 weeks, with no change in lipids or blood pressure. Glycaemic gains were limited to underpowered obese and insulin-resistant subgroups.
Expert Commentary
This is a reasonable nutritional trial whose real result is narrower than an enthusiastic reading suggests, and accuracy matters here. The one robust finding is a reduction in insulin resistance with the high-phenolic oil, which is biologically plausible given the antioxidant and anti-inflammatory properties of olive polyphenols. But contrary to the earlier framing, lipids and blood pressure did not significantly improve in either arm, and the eye-catching glucose and HbA1c reductions were confined to obese and insulin-resistant subgroups that the authors themselves flag as underpowered and provisional. So this is a signal that phenolic-rich olive oil may aid insulin sensitivity, not proof that it broadly controls blood sugar, lipids, and pressure. The comparator design, refined versus high-phenolic oil, is also a fair test of the phenolics specifically rather than of olive oil versus nothing. Can I use this with my patients? Yes, in a measured, dietary way. It reinforces recommending extra virgin, polyphenol-rich olive oil as the preferred fat within a Mediterranean-style diet for diabetic patients, while being honest that the firm benefit here is on insulin resistance, and that the subgroup glycaemic findings need larger confirmation.
References
Figueiredo-González M, Seoane-Cruz I, Reboredo-Rodríguez P, et al. Exploring Galician phenolic-rich olive oil as a glycemic control strategy: the OILDIABET randomized trial. Food Funct. 2025;16(15):6213–6230. doi:10.1039/d5fo00873e